www.fdanews.com/articles/152974-the-european-medicines-agency-approves-aripiprazole-for-the-treatment-of-moderate-to-severe-manic-episodes-in-bipolar-i-disorder-in-adolescents
The European Medicines Agency Approves Aripiprazole for the Treatment of Moderate to Severe Manic Episodes in Bipolar I Disorder in Adolescents
February 6, 2013
Otsuka Pharmaceutical announced that the European Medicines Agency has approved a label extension for aripiprazole for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 and older.
Otsuka Pharmaceutical
Otsuka Pharmaceutical